These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23614779)

  • 1. Reply to "mTOR inhibitor-related pulmonary toxicity; incidence even higher".
    Palazzo A; Iacovelli R; Cortesi E
    Acta Oncol; 2013 Aug; 52(6):1235. PubMed ID: 23614779
    [No Abstract]   [Full Text] [Related]  

  • 2. mTOR inhibitor-related pulmonary toxicity; incidence even higher.
    Willemsen AE; van Herpen CM
    Acta Oncol; 2013 Aug; 52(6):1234. PubMed ID: 23409770
    [No Abstract]   [Full Text] [Related]  

  • 3. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
    Iacovelli R; Palazzo A; Mezi S; Morano F; Naso G; Cortesi E
    Acta Oncol; 2012 Sep; 51(7):873-9. PubMed ID: 22909392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.
    Peddi PF; Shatsky RA; Hurvitz SA
    Cancer Treat Rev; 2014 Mar; 40(2):320-6. PubMed ID: 24011786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.
    Duran I; Goebell PJ; Papazisis K; Ravaud A; Weichhart T; Rodriguez-Portal JA; Budde K
    Expert Opin Drug Saf; 2014 Mar; 13(3):361-72. PubMed ID: 24517115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.
    Zhang X; Ran YG; Wang KJ
    Future Oncol; 2016 Jun; 12(12):1529-39. PubMed ID: 27067269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of mTOR in aging and cancer.
    Zhavoronkov A
    Oncotarget; 2015 Dec; 6(42):45010-1. PubMed ID: 26942715
    [No Abstract]   [Full Text] [Related]  

  • 8. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.
    Willemsen AE; Grutters JC; Gerritsen WR; van Erp NP; van Herpen CM; Tol J
    Int J Cancer; 2016 May; 138(10):2312-21. PubMed ID: 26452336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [mTOR inhibitor].
    Muro K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular side effects of small molecule therapies for cancer.
    Pun SC; Neilan TG
    Eur Heart J; 2016 Sep; 37(36):2742-2745. PubMed ID: 27694541
    [No Abstract]   [Full Text] [Related]  

  • 11. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus: side effect profile and management of toxicities in breast cancer.
    Paplomata E; Zelnak A; O'Regan R
    Breast Cancer Res Treat; 2013 Aug; 140(3):453-62. PubMed ID: 23907751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibitors in cancer therapy.
    Zaytseva YY; Valentino JD; Gulhati P; Evers BM
    Cancer Lett; 2012 Jun; 319(1):1-7. PubMed ID: 22261336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
    Lebwohl D; Anak O; Sahmoud T; Klimovsky J; Elmroth I; Haas T; Posluszny J; Saletan S; Berg W
    Ann N Y Acad Sci; 2013 Jul; 1291():14-32. PubMed ID: 23659703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Toxicity management for mTOR inhibitors].
    Mukohara T
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():272-6. PubMed ID: 25831766
    [No Abstract]   [Full Text] [Related]  

  • 16. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.
    García-Echeverría C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4308-12. PubMed ID: 20561789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of mTOR-inhibitors in solid tumors].
    Seidel C; Grünwald V
    Med Monatsschr Pharm; 2011 Apr; 34(4):116-26; quiz 127-8. PubMed ID: 21528529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
    Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.
    Ekman S; Wynes MW; Hirsch FR
    J Thorac Oncol; 2012 Jun; 7(6):947-53. PubMed ID: 22588151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
    Perricone G; Mancuso A; Belli LS; Mazzarelli C; Zavaglia C
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):577-8. PubMed ID: 24694739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.